This document provides an overview of a company called Aerie Pharmaceuticals and their glaucoma products. It summarizes results from clinical trials of their two leading investigational drug candidates, Rhopressa and Roclatan. Rhopressa achieved non-inferiority compared to timolol in lowering eye pressure over 6 months in phase 3 trials. A pilot study also found Rhopressa to be effective at lowering pressure during nighttime hours. Roclatan was found to be statistically superior to its individual components, latanoprost and Rhopressa, in lowering pressure at all timepoints in a phase 3 trial. Both drugs demonstrated favorable safety profiles in clinical testing.

1. Company Overview
OIS @ ASCRS
May 4, 2017
MLR-0035 New Investigational Drug OIS @ ASCRS 2017

2. Important Information
Any discussion of the potential use or expected success of our product candidates is subject to our product candidates
being approved by regulatory authorities.
The information in this presentation is current only as of its date and may have changed or may change in the future.
We undertake no obligation to update this information in light of new information, future events or otherwise. We are not
making any representation or warranty that the information in this presentation is accurate or complete.
Certain statements in this presentation are “forward-looking statements” within the meaning of the federal securities
laws. Words such as “may,” “will,” “should,” “would,” “could,” “believe,” “expects,” “anticipates,” “plans,” “intends,”
“estimates,” “targets,” “projects,” “potential” or similar expressions are intended to identify these forward-looking
statements. These statements are based on the Company’s current plans and expectations. Known and unknown risks,
uncertainties and other factors could cause actual results to differ materially from those contemplated by the
statements. In evaluating these statements, you should specifically consider various factors that may cause our actual
results to differ materially from any forward-looking statements. These risks and uncertainties are described more fully
in the quarterly and annual reports that we file with the SEC, particularly in the sections titled “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In particular, the topline
Rocket 4 data presented herein is preliminary and based solely on information available to us as of the date of this
press release and additional information about the results may be disclosed at any time. Such forward-looking
statements only speak as of the date they are made. We undertake no obligation to publicly update or revise any
forward-looking statements, whether because of new information, future events or otherwise, except as otherwise
required by law.
2

3. 3
Aerie Current Glaucoma Products – Patented thru 2030
Pre-Clinical Research
• Rhopressa
™
• Improved aqueous outflow via the trabecular meshwork
• Anti-fibrotic activity in cultured human trabecular meshwork cells
• AR-13154
• Significant lesion size reduction in wet AMD model
• Rhopressa
™
(netarsudil ophthalmic solution) 0.02%
• Inhibits ROCK, NET, lowers EVP, targets diseased tissue
• NDA resubmitted in February 2017; entering launch mode
• Roclatan
™
(netarsudil / latanoprost ophthalmic solution) 0.02% / 0.005%
• Fixed combination of Rhopressa
™
and latanoprost
• Two Phase 3’s in process; first P3 achieved primary efficacy endpoint
Aerie – Building a Major Ophthalmic Pharmaceutical
Company
Data on file OIS @ ASCRS 2017

4. 44
RhopressaTM
Once-Daily Efficacy Performance: Summary To
Date
Well researched by 200+ eye doctors in over 2,000 clinical patients
Once-daily efficacy demonstrated in 4 Phase 3 trials achieving non-inferiority vs B.I.D. timolol (Rocket 1, 2, 4) and latanoprost (Mercury
1) in subjects with baseline IOP < 25 mmHg
Stable IOP lowering through 12 months, no evidence of “IOP drift”
Initial evidence of 24-hour IOP control
Additional differentiating attributes e.g., trabecular meshwork outflow and anti-fibrotic effects
OIS @ ASCRS 2017

5. Rocket 4: RhopressaTM
Achieved Non-Inferiority in the Primary
Efficacy Analysis (Baseline IOP < 25 mmHg)
Mean IOP at Each Time Point (PP) – Topline 6-Month
5
• Rhopressa
™
performance remained within the non-inferiority range
through 6 months
++Data on File
Based on Rocket 4 Topline 6-month safety

6. Rocket 4: RhopressaTM
Efficacy Stable through 6 Months
(8 AM IOP)
Baseline < 27 mmHg
Rhopressa™ (n=xx)
BL W2 W6 M3 M4 M5 M6
++Data on File
Based on Rocket 4 Topline 6-month 8am IOP
6
BL W2 W6 M3 M4 M5 M6
Baseline < 25 mmHg
Rhopressa™ (n=186) Rhopressa™ (n=240)

7. 7
Rhopressa™
24-hour IOP Pilot Study
Demonstrates Effective Nocturnal Efficacy
Rhopressa™
(n=8)
Baseline
(n=8)
**
**
**
***
**
**
*** ***
** p<0.01
*** p<0.001
• Rhopressa™ equally effective during nocturnal and diurnal periods
• Current glaucoma medications either have no efficacy at night (beta blockers, alpha agonists) or reduced efficacy
at night (PGAs, CAIs)
1 - 6
Data on File: AR-13324-CS204
1. Liu JH, et al. Am J Ophthalmol. 2004; 138:389-395. 2. Gulati V, et al. Arch Ophthalmol. 2012; 130:677-684. 3. Liu JH, et al. Ophthalmology. 2009; 116:449-454. 4. Liu JH, et al.
Ophthalmology. 2010; 117:2075-9. 5. Fan S et al. J Glaucoma. 2014; 23:276-81. 6. Liu JH, et al. Am J Ophthalmol. 2016;169:249-257.
Pre-dose
Post-dose (Day 8/9)

8. 88
RhopressaTM
Once-Daily Safety Performance: Summary To
Date
Well tolerated with no evidence of treatment-related serious or systemic AEs
Most common AE: conjunctival hyperemia, ~48% incidence
- mild for ~75% of patients and sporadic; only 10% of subjects had hyperemia at each study visit.
- 4% discontinued due to hyperemia.
20% of subjects had hyperemia at post-washout baseline prior to initiating treatment
AEs occurring in ~5-25% of subjects included: cornea verticillata, conjunctival hemorrhage (petechiae), lacrimation increased,
erythema of eyelid and vision blurred

9. 9
RoclatanTM
Achieved Statistical Superiority Over Individual
Components At All 9 Time Points
Mean IOP at Each Time Point (ITT)
***p<0.0001 vs Latanoprost and RhopressaTM
Data on File
In Mercury 1, Roclatan™ IOP lowering was 1-3 mmHg greater than
monotherapy with latanoprost or Rhopressa™
Mean IOP at Each Time Point (ITT)

10. 10
Mercury 1: RoclatanTM
Phase 3 Responder Analysis
Day 90: % of Patients with IOP Reduced to 18 mmHg or Lower
***
***
***
14%
23%
32%
42%
54%
15%
25%
39%
54%
69%
33%
44%
61%
71%
82%
0%
20%
40%
60%
80%
100%
≤ 14 mmHg ≤ 15 mmHg ≤ 16 mmHg ≤ 17 mmHg ≤ 18 mmHg
%ofPatients
IOP on Treatment
Rhopressa™ (n=198) Latanoprost (n=223) Roclatan™ (n=200)
###
###
***p<0.0001 vs Latanoprost and RhopressaTM
###p<0.0001 vs RhopressaTM, p<0.05 vs Latanoprost
Data on file and PG324 - CS301

11. 11
Mercury 1: Safety/Tolerability Overview of RoclatanTM
• There were no drug-related serious or systemic adverse events
• The most common adverse event was conjunctival hyperemia with
~50% incidence*, ~80% mild on biomicroscopy
• Other ocular AEs
– AEs occurring in ~5-11% of subjects receiving RoclatanTM
included: conjunctival hemorrhage, eye pruritus, lacrimation
increased and cornea verticillata.
* Incidence of conjunctival hyperemia ~50% including baseline at ~20%
Data on file and PG324 - CS301

12. Aerie Corporate Advertisements
12